Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 233 shares of Axsome Therapeutics stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $228.18, for a total value of $53,165.94. Following the transaction, the chief operating officer directly owned 4,517 shares of the company's stock, valued at $1,030,689.06. This trade represents a 4.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Axsome Therapeutics Trading Down 0.3%
NASDAQ:AXSM opened at $223.06 on Wednesday. The company has a market capitalization of $11.47 billion, a PE ratio of -59.80 and a beta of 0.59. The company has a quick ratio of 1.48, a current ratio of 1.55 and a debt-to-equity ratio of 1.38. Axsome Therapeutics, Inc. has a 52-week low of $96.09 and a 52-week high of $234.29. The stock has a fifty day simple moving average of $171.73 and a 200-day simple moving average of $163.34.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The firm had revenue of $191.20 million for the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics had a negative return on equity of 246.90% and a negative net margin of 26.59%.The firm's revenue was up 57.4% on a year-over-year basis. On average, equities research analysts expect that Axsome Therapeutics, Inc. will post -1.05 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on AXSM shares. TD Cowen reissued a "buy" rating on shares of Axsome Therapeutics in a research note on Friday. Royal Bank Of Canada boosted their target price on shares of Axsome Therapeutics from $242.00 to $302.00 and gave the company an "outperform" rating in a research note on Tuesday. Wolfe Research started coverage on shares of Axsome Therapeutics in a research note on Monday, February 23rd. They issued an "outperform" rating and a $230.00 target price for the company. Wells Fargo & Company boosted their target price on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company an "overweight" rating in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft set a $280.00 target price on shares of Axsome Therapeutics in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $251.89.
Read Our Latest Research Report on Axsome Therapeutics
Axsome Therapeutics News Roundup
Here are the key news stories impacting Axsome Therapeutics this week:
- Positive Sentiment: Very strong top-line growth — 1Q net product revenue of $191.2M, up ~57% YoY, driven by AUVELITY ($153.2M) and SUNOSI ($33.9M); this validates commercial traction for Axsome’s lead products. Axsome 1Q 2026 Financial Results
- Positive Sentiment: Multiple analyst price-target lifts today (notably Mizuho to $310, Wells Fargo to $255, Baird to $246, Morgan Stanley to $242) and continued “buy/outperform” coverage increase perceived upside and support near-term sentiment. Analyst Coverage & Price Target Moves
- Positive Sentiment: Pipeline and corporate catalysts remain in play — AUVELITY approval for agitation in Alzheimer’s, NDA submission for AXS‑12 (cataplexy), addition of AXS‑20 to the pipeline — these can drive medium/long-term upside. Business Update & Pipeline Highlights
- Neutral Sentiment: Management outreach: Axsome will participate in multiple investor conferences (BofA fireside chat, others) — useful for additional disclosure but timing/impact is uncertain. Investor Conference Participation
- Neutral Sentiment: Full earnings and call transcripts are available for deeper read-throughs; analysts and commentators are parsing sequential trends and guidance in detail. Earnings Call Transcript & Analysis
- Negative Sentiment: Earnings miss: GAAP EPS of ($1.26) vs. consensus (~$0.85 loss) — the wider loss and negative margins/ROE raise near-term profitability concerns despite revenue strength. Q1 Loss Widens; Revenues Jump (Zacks)
- Negative Sentiment: Some skepticism on sustainability — commentary notes sequential sales dips for key products and questions about achievability of management’s long‑term peak revenue targets, which could temper enthusiasm. Earnings Review & Skepticism (Seeking Alpha)
Institutional Trading of Axsome Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Axsome Therapeutics by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company's stock valued at $507,739,000 after buying an additional 235,626 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Axsome Therapeutics by 45.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company's stock valued at $275,763,000 after buying an additional 472,422 shares during the period. Wellington Management Group LLP raised its holdings in shares of Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company's stock worth $162,082,000 after purchasing an additional 609,516 shares during the period. Invesco Ltd. raised its holdings in shares of Axsome Therapeutics by 28.6% in the 4th quarter. Invesco Ltd. now owns 1,273,494 shares of the company's stock worth $232,591,000 after purchasing an additional 282,937 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Axsome Therapeutics by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company's stock worth $184,544,000 after purchasing an additional 12,549 shares during the period. Hedge funds and other institutional investors own 81.49% of the company's stock.
Axsome Therapeutics Company Profile
(
Get Free Report)
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.
Axsome's pipeline includes several late-stage and approved product candidates.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
